Avraham initiates ladostigil Stage 2 trial in MCI Avraham Pharmaceuticals Ltd.

Weinstock-Rosin, ladostigil provides showed guarantee also for the treating MCI furthermore to Alzheimer’s disease. We have been pleased that another Stage 2 medical trial in patients with MCI has started in parallel, and appearance forward to the ultimate results of the Phase 2 research for the treating Alzheimer’s disease anticipated at the end of the year. I am delighted to business lead Avraham in these interesting times for the business, once we advance ladostigil in 2 Phase 2 scientific trials simultaneously. We believe that this original drug candidate gets the potential to transform the treating various neurodegenerative illnesses, said Dr.In the lack of this provision for reduction, gross income for the quarter could have been $656,000 or 23.7 percent of revenue which is in keeping with the gross profit margin achieved in prior quarters. For the six month period gross revenue decreased by $2,200,000, an 85 percent lower from the gross revenue of $2,585,june 30 000 documented for the half a year ended, 2013. Operating expenditures in the one fourth of $748,000 had been 31 percent less than the $1,088,000 of expenditures documented in the same period in the last year. June 30 For the half a year ended, 2014 operating expenditures were $1,482,000, a 29 percent lower over operating expenditures of $2,073,000 in the similar period in 2013. The reduction in operating expenditures were largely the full total result of lower product sales commissions earned on the low revenue recorded, and by lower general and administrative costs and lower expenditures on study and development caused by price reductions initiated by the business.